FILING BY "EXPRESS MAIL" U

EXTOY6206274S
Express Mail Label Number

20. Other items or information: Unexecuted Declaration and Power of Attorney

	10-96		Department of Commerce Fatent and Trademark Office	ON/4-33248A									
		TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)										
		DESIGNATED/ELECTED O	10/561757										
CONCERNING A FILING UNDER 35 U.S.C. 371													
		NATIONAL APPLICATION NO.	PRIORITY DATE CLAIMED										
PCT/EP2004/006921													
	CANCER TREATMENT WITH EPOTHILONES												
		CANT(S) FOR DO/EO/US											
PARKINSON ET AL.													
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.	$\boxtimes$	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.											
2. 3.		This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay											
4.	$\boxtimes$	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority											
5.	$\boxtimes$	date. A copy of the International Application as	s filed (35 U.S.C. 371(c)(2))										
		a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau). b. ☑ has been transmitted by the International Bureau. (See Form PCT/IB/308)											
_	_	c. is not required, as the application was filed in the United States Receiving Office (RO/US).											
6. 7.		A translation of the International Application Amendments to the claims of the International Amendments to the claims of the International Amendments to the claims of the International Amendments and International Amend		(35 U.S.C.371(c)(3)).									
		a. are transmitted herewith (require	d only if not transmitted by the Internation										
	<ul> <li>b.  have been transmitted by the International Bureau.</li> <li>c.  have not been made; however, the time limit for making such amendments has NOT expired.</li> </ul>												
0		d. 🛛 have not been made and will not	be made.	•									
8. 9.	$\exists$	A translation of the amendments to the can executed Declaration and Power of A											
10.		under PCT Article 36 (35 U.S.C.											
371(c)(5)).													
lter	ns 1	1. to 16. below concern document(s) o	r information included.										
11.		An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.										
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.											
13.	$\boxtimes$	A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	rv amendment.										
14.	⊠	An Application Data Sheet under 37 CFF											
15.		A substitute specification.											
16.		A change of power of attorney and/or ad	dress letter.										
17.		A computer-readable form of the sequer	nce listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821-1.825.									
18.		A second copy of the published Internati	onal Application under 35 U.S.C. 154(d)	(4).									
19.		A second copy of the English language	ranslation of the International application	n under 35 U.S.C. 154(d)(4).									

## IAPS ROC'S PCT/PTO 21 DEC 2009

U.S. APPLICATION NO. (if pown.gep.37 CFR.45) 7 5 INTERNATIONAL APPLICATION NO. ATTORNEY'S D. ON/4-3324								OCKET NUMBER				
The following fees are submitted:									CALCULATIONS PTO USE			
								ONLY				
21. 🛭 Basid	c nationa	ıl fee					\$300					
22. Examination Fee												
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)												
<u></u>												
☑ All other situations												
23. Search fee												
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international												
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400												
All other situations												
TOTAL OF 21, 22 AND 23 =												
TOTAL OF 21, 22 AND 23 = \$900  Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer												
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.												
Total Sheets	Extra	sheets		ach additional 50 or fraction	on	R	ATE					
51 - 100 =	0	/50 =	thereof (round	d <b>up</b> to a whole number)	$\dashv$	X \$	250	\$				
**							200	-				
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).												
CLAIMS		NUMBE	R FILED	NUMBER EXTRA		RA	ТЕ					
Total claims	·	41	- 20 =	21	×		50	\$	1,050			
Independent cla		<u>                                     </u>		0	X   +		200 360	\$ \$				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =												
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be												
filed (Note 37 CFR 1.9, 1.27, 1.28).  SUBTOTAL =												
				ranslation later than	30 m			\$	1,950			
earliest claimed	priority o	date (37 CFI	R 1.492(f)).			=	+	\$	4 0 5 0			
Fee for recording	a the en	closed assis	romont (37 CE	R 1.21(h)). The assignm			AL FEE =	\$	1,950			
				). \$40 per property			+	\$				
				TOTAL	. FEE	ES ENC	LOSED =	\$	1,950			
									nount to	\$		
									efunded charged	\$		
a. A chec	k in the	amount of \$		to cover the above fe	es is	enclosed.						
			ount No. 19-0	134 in the name of Nova	tis in	the amou	nt of \$1,950	o cove	r the abo	ve fees. A		
				to charge any additional f	ees w	hich mav	be required.	or cred	lit anv ove	erpayment to		
	it Accour	nt No. 19-01	34 in the name	e of Novartis.					,			
				37 CFR 1.494 or 1.495 h application to pending			et, a petition	to rev	ive (37 C	FR 1.137(a)		
	Send all correspondence to the address associated with											
Customer No. 001095, which is currently:												
Oona A. Jackson / Novartis Attorney for Applicants								J				
Corporate Intellectual Property Reg. No. 48,152												
One Health Plaza, Building 104 (862) 778-7852 East Hanover, NJ 07936-1080												
200.110		5. 555 10										